<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091295</url>
  </required_header>
  <id_info>
    <org_study_id>AF19-200</org_study_id>
    <nct_id>NCT04091295</nct_id>
  </id_info>
  <brief_title>BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer and Sarcoma</brief_title>
  <official_title>BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer and Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aveni Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aveni Foundation</source>
  <brief_summary>
    <textblock>
      Twenty to forty patients will receive DeltaRex-G intravenously at a dose of 3 x 10e11 colony&#xD;
      forming units (cfu) or equivalent 1.6 x 10e10 Neo Units (60 ml) per dose three times a week&#xD;
      for 3 weeks followed by one week rest. Based on previous Phase 1/2 US based clinical studies,&#xD;
      DeltaRex-G does not suppress the bone marrow or cause serious organ dysfunction, and enhanced&#xD;
      immune cell trafficking in tumors may cause the tumors to appear larger or new lesions to&#xD;
      appear on CT, PET or MRI. Further, tumor stabilization/regression/remission may occur later&#xD;
      during the treatment period. Therefore, DeltaRex-G will be continued regardless of CT, PET or&#xD;
      MRI results if the patient has clinical benefit and does not have symptomatic disease&#xD;
      progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty to forty patients with advanced pancreatic cancer and sarcoma will receive DeltaRex-G&#xD;
      intravenously at a dose of 3 x 10e11 colony forming units (cfu) or equivalent 1.6 x 10e10 Neo&#xD;
      Units (60 ml) per dose three times a week for 3 weeks followed by one week rest. Based on&#xD;
      previous Phase 1/2 US based clinical studies, DeltaRex-G does not suppress the bone marrow or&#xD;
      cause serious organ dysfunction, and enhanced immune cell trafficking in tumors may cause the&#xD;
      tumors to appear larger or new lesions to appear on CT, PET or MRI. Further, tumor&#xD;
      stabilization/regression/remission may occur later during the treatment period. Therefore,&#xD;
      DeltaRex-G will be continued regardless of CT, PET or MRI results if the patient has clinical&#xD;
      benefit and does not have symptomatic disease progression.&#xD;
&#xD;
      If the patient develops a treatment-related &gt;Grade 3 adverse event, the DeltaRex-G infusions&#xD;
      will be held and the patient will be monitored until the toxicity has resolved to &lt;Grade 1,&#xD;
      and the patient is stable, after which treatment may be resumed. If the adverse event does&#xD;
      not resolve to &lt;Grade 1 within 3 weeks, the DeltaRex-G treatment will be held until the data&#xD;
      are discussed with the Food and Drug Administration and a decision is made whether to&#xD;
      continue or terminate the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Pancreatic Cancer</condition>
  <condition>Osteosarcoma</condition>
  <condition>MPNST (Malignant Peripheral Nerve Sheath Tumor)</condition>
  <condition>Chondrosarcoma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Chordoma</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DeltaRex-G</intervention_name>
    <description>Intravenous infusions of DeltaRex-G for treatment of advanced pancreatic cancer and sarcoma that have failed standard therapies</description>
    <other_name>DeltaRex-G Retroviral Vector Encoding a Cyclin G1 Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is ≥10 years of age, either male or female.&#xD;
&#xD;
          -  Patient has advanced metastatic pancreatic cancer or advanced metastatic sarcoma&#xD;
             confirmed by pathologic examination at diagnosis.&#xD;
&#xD;
          -  Patients with advanced metastatic pancreatic cancer who have received systemic&#xD;
             therapies such as FOLFIRINOX and gemcitabine + albumin-bound paclitaxel; patients with&#xD;
             metastatic sarcoma who have disease progression after two or more lines of systemic&#xD;
             treatments and not amenable to surgical resection or radiotherapy; specifically for&#xD;
             osteosarcoma: have disease progression after high dose methotrexate, cisplatinum,&#xD;
             doxorubicin and ifosfamide; for soft tissue sarcoma: have disease progression after&#xD;
             doxorubicin + ifosfamide/mesna, gemcitabine, docetaxel, dacarbazine, trabectedin,&#xD;
             pazopanib, eribulin ; patient who is intolerant to or declines available therapeutic&#xD;
             options after documentation that patient has been informed of the available&#xD;
             therapeutic options.&#xD;
&#xD;
          -  Patient is able to understand or is willing to sign a written informed consent.&#xD;
&#xD;
          -  Patient agrees to use barrier contraception during vector infusion period and for 6&#xD;
             weeks after infusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is unwilling to provide formal informed consent.&#xD;
&#xD;
          -  Patient is unwilling to use barrier contraception during vector infusion period and&#xD;
             for 6 weeks after infusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ERLINDA M GORDON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sarcoma Oncology Research Center, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ERLINDA M GORDON, MD</last_name>
    <phone>3105529999</phone>
    <email>egordon@sarcomaoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victoria Chua-Alcala, MD</last_name>
    <phone>3105529999</phone>
    <email>vchua@sarcomaoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center, LLC</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>ERLINDA M GORDON, MD</last_name>
      <phone>310-552-9999</phone>
      <email>egordon@sarcomaoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Chua-Alcala, MD</last_name>
      <phone>3105529999</phone>
      <phone_ext>Chawla</phone_ext>
      <email>santchawla@sarcomaoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sant P Chawla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Wong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doris Quon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ania M Moradkhani, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chawla SP, Chawla NS, Quon D, Chua-Alcala V, Blackwelder WC, Hall FL and Gordon EM: An advanced phase 1/2 study using an XC-targeted gene therapy vector for chemotherapy resistant sarcoma. Sarcoma Res Int 3: 1024, 2016</citation>
  </reference>
  <reference>
    <citation>Gordon EM, Hall FL. Rexin-G, a targeted genetic medicine for cancer. Expert Opin Biol Ther. 2010 May;10(5):819-32. doi: 10.1517/14712598.2010.481666. Review.</citation>
    <PMID>20384524</PMID>
  </reference>
  <reference>
    <citation>Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, Hall FL, Gordon EM. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma. Mol Ther. 2009 Sep;17(9):1651-7. doi: 10.1038/mt.2009.126. Epub 2009 Jun 16.</citation>
    <PMID>19532136</PMID>
  </reference>
  <reference>
    <citation>Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Mol Ther Oncolytics. 2018 Dec 14;12:56-67. doi: 10.1016/j.omto.2018.12.005. eCollection 2019 Mar 29.</citation>
    <PMID>30705966</PMID>
  </reference>
  <reference>
    <citation>Al-Shihabi A, Chawla SP, Hall FL, Gordon EM. Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy. Mol Ther Oncolytics. 2018 Dec 12;11:122-126. doi: 10.1016/j.omto.2018.11.002. eCollection 2018 Dec 21. Review.</citation>
    <PMID>30581985</PMID>
  </reference>
  <results_reference>
    <citation>Kim S, Federman N, Gordon EM, Hall FL, Chawla SP. Rexin-G(®), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. Mol Clin Oncol. 2017 Jun;6(6):861-865. doi: 10.3892/mco.2017.1231. Epub 2017 Apr 28.</citation>
    <PMID>28588778</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aveni Foundation</investigator_affiliation>
    <investigator_full_name>Erlinda M Gordon</investigator_full_name>
    <investigator_title>Chief Medical Officer</investigator_title>
  </responsible_party>
  <keyword>tumor targeted gene therapy</keyword>
  <keyword>human cyclin G1 inhibitor</keyword>
  <keyword>cell cycle control</keyword>
  <keyword>CCNG1 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Chordoma</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurofibrosarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

